Related Experiment Video
Updated: Mar 1, 2026

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
Published on: January 27, 2023
Statins do not inhibit the FGFR signaling in chondrocytes
B Fafilek1, M Hampl2, N Ricankova3
1Department of Biology, Faculty of Medicine, Masaryk University, 62500, Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital, 65691, Brno, Czech Republic.
Objective:
Statins are widely used drugs for cholesterol lowering, which were recently found to counteract the effects of aberrant fibroblast growth factor receptor (FGFR3) signaling in cell and animal models of FGFR3-related chondrodysplasia. This opened an intriguing therapeutic possibility for human dwarfing conditions caused by gain-of-function mutations in FGFR3, although the mechanism of statin action on FGFR3 remains unclear. Here, we determine the effect of statins on FGFR signaling in chondrocytes.
Design:
Cultured chondrocyte cell lines, mouse embryonic tibia cultures and limb bud micromasses were treated with FGF2 to activate FGFR signaling. The effects of atorvastatin, fluvastatin, lovastatin and pravastatin on FGFR3 protein stability and on FGFR-mediated chondrocyte growth-arrest, loss of extracellular matrix (ECM), induction of premature senescence and hypertrophic differentiation were evaluated.
Results:
Statins did not alter the level of FGFR3 protein expression nor produce any effect on FGFR-mediated inhibition of chondrocyte proliferation and hypertrophic differentiation in cultured chondrocyte cell lines, mouse tibia cultures or limb bud micromasses.
Conclusion:
We conclude that statins do not inhibit the FGFR signaling in chondrocytes. Therefore the statin-mediated rescue of FGFR3-related chondrodysplasia, described before, is likely not intrinsic to the growth plate cartilage.
Insights
Statins do not inhibit fibroblast growth factor receptor 3 (FGFR3) signaling in chondrocytes. This suggests statin benefits for FGFR3-related chondrodysplasia may not originate within growth plate cartilage.
Area of Science:
- Cell Biology
- Molecular Biology
- Genetics
Background:
- Statins, cholesterol-lowering drugs, may counteract aberrant fibroblast growth factor receptor 3 (FGFR3) signaling.
- FGFR3 mutations cause human dwarfing conditions, presenting a potential therapeutic target for statins.
- The mechanism of statin action on FGFR3 signaling remains unclear.
Purpose of the Study:
- To investigate the effect of statins on FGFR signaling in chondrocytes.
- To determine if statins can inhibit FGFR3-mediated effects in cartilage cells.
Main Methods:
- Primary chondrocytes, mouse embryonic tibia, and limb bud micromasses were treated with FGF2 to activate FGFR signaling.
- The effects of four statins (atorvastatin, fluvastatin, lovastatin, pravastatin) were evaluated.
- Assessed FGFR3 protein stability and FGFR-mediated chondrocyte growth arrest, ECM loss, senescence, and differentiation.
Main Results:
- Statins did not alter FGFR3 protein expression levels.
- No statin treatment affected FGFR-mediated inhibition of chondrocyte proliferation.
- Statins did not impact FGFR-mediated hypertrophic differentiation in any model system.
Conclusions:
- Statins do not inhibit FGFR signaling within chondrocytes.
- The previously observed statin-mediated rescue of FGFR3-related chondrodysplasia is unlikely to be an intrinsic effect of the growth plate cartilage.
- Further research is needed to elucidate the mechanism behind statin's therapeutic effects in chondrodysplasia models.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
TGF - β Signaling Pathway

